Market Overview:
The global lipid metabolism disease treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of obesity and diabetes, rising geriatric population, and technological advancements in the field of lipid metabolism disease treatment. The global lipid metabolism disease treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into OTC drugs and Rx drugs. The OTC drugs segment is expected to grow at a higher CAGR than that of Rx drugs during the forecast period owing to their easy availability and low cost as compared to Rx drugs. On the basis of application,the hospital segment dominatesthe global lipid metabolism disease treatment market followed by retail pharmacy due tot he high incidence rateof these diseasesin hospitalsand growing demand for better healthcare facilities worldwide .
Product Definition:
Lipid metabolism disease treatment is the use of medications or other treatments to correct problems with how the body breaks down and uses fats. These treatments are important because they can help prevent or treat serious health problems such as heart disease, diabetes, and obesity.
OTC:
OTC stands for Over-the-Counter and is a market that consists of drugs which are used to treat minor ailments like common cold, allergies, skin rashes, etc. OTC drug market has been experiencing significant growth over the past few years due to increased consumer awareness regarding self-health care management coupled with rising disposable income in developing countries such as India and China.
Rx Drugs:
Rx drugs and it's usage in lipid metabolism disease treatment market is expected to witness lucrative growth over the forecast period owing to increasing prevalence of lifestyle diseases such as obesity, diabetes, and cardiovascular disorders. According to the Centers for Disease Control (CDC), more than one-third population of U.S is either obese or overweight which leads to increased incidences of chronic diseases including heart failure, stroke, Chronic Obstructive Pulmonary Disease (COPD) & asthma among others.
Application Insights:
The global market is categorized into hospital, retail pharmacy and others.
Hyperlipidemia is a common disorder affecting people across the globe due to unhealthy lifestyle habits such as excessive intake of saturated fatty acids and cholesterol along with lack of physical exercise. As per the National Center for Biotechnology Information (NCBI), around 60 million individuals are affected by this disorder in U.S., resulting in approximately 3,000 deaths every year due to cardiovascular diseases caused due to high blood pressure levels associated with it. This factor is anticipated to fuel product demand over the forecast period thus driving growth during future years too.
Regional Analysis:
North America accounted for the largest share of over 40.0% in 2017 owing to the presence of a large number of global players and high adoption rate for novel treatment options. The market is driven by growing prevalence, increasing demand for quality care, rising expenditure on healthcare, and availability of effective treatment methods in this region.
Asia Pacific is expected to be one of the fastest-growing regions during the forecast period due to factors such as improving economic conditions leading to increased disposable income and rapid urbanization resulting in an increase in population suffering from lipid metabolism diseases. Moreover, government initiatives are undertaken that focus on disease management through early diagnosis which will drive growth further. For instance, BAYER AG launched its new drug Baycol (apalutamide) at low cost in India thereby making it more accessible & affordable for patients there (1).
In addition it was approved by FDA under Priority Review Program which allowed faster approval process than regular reviews thus boosting sales further (2).
Growth Factors:
- Increasing prevalence of lipid metabolism diseases such as obesity, diabetes, and heart disease is expected to drive the market growth.
- Rising awareness about the benefits of lipid metabolism disease treatment is anticipated to propel the market growth.
- Technological advancements in diagnosis and treatment of lipid metabolism diseases are projected to boost the market growth over the forecast period.
- Growing demand for minimally invasive procedures for treating lipid metabolism diseases is likely to fuel market expansion during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Lipid Metabolism Disease Treatment Market Research Report
By Type
OTC, Rx Drugs
By Application
Hospital, Retail Pharmacy
By Companies
Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin, LG Life Science, Metsubishi Tanabe Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
161
Number of Tables & Figures
113
Customization Available
Yes, the report can be customized as per your need.
Global Lipid Metabolism Disease Treatment Market Report Segments:
The global Lipid Metabolism Disease Treatment market is segmented on the basis of:
Types
OTC, Rx Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Retail Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Novartis
- Takeda Pharmaceutical
- Astra Zeneca
- Boehringer Ingelheim
- KOWA
- Kythera
- Fuji yakuhin
- LG Life Science
- Metsubishi Tanabe Pharma
Highlights of The Lipid Metabolism Disease Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- OTC
- Rx Drugs
- By Application:
- Hospital
- Retail Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lipid Metabolism Disease Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lipid metabolism disease treatment is a combination of medications and lifestyle changes that are aimed at improving the patient's lipid levels. Treatment may include medication, diet, and exercise.
Some of the major companies in the lipid metabolism disease treatment market are Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin, LG Life Science, Metsubishi Tanabe Pharma.
The lipid metabolism disease treatment market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lipid Metabolism Disease Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Lipid Metabolism Disease Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Lipid Metabolism Disease Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Lipid Metabolism Disease Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Lipid Metabolism Disease Treatment Market Size & Forecast, 2020-2028
4.5.1 Lipid Metabolism Disease Treatment Market Size and Y-o-Y Growth
4.5.2 Lipid Metabolism Disease Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 OTC
5.2.2 Rx Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Retail Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lipid Metabolism Disease Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lipid Metabolism Disease Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 OTC
9.6.2 Rx Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Retail Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 OTC
10.6.2 Rx Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Retail Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 OTC
11.6.2 Rx Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Retail Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 OTC
12.6.2 Rx Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Retail Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 OTC
13.6.2 Rx Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Retail Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lipid Metabolism Disease Treatment Market: Competitive Dashboard
14.2 Global Lipid Metabolism Disease Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck
14.3.2 Novartis
14.3.3 Takeda Pharmaceutical
14.3.4 Astra Zeneca
14.3.5 Boehringer Ingelheim
14.3.6 KOWA
14.3.7 Kythera
14.3.8 Fuji yakuhin
14.3.9 LG Life Science
14.3.10 Metsubishi Tanabe Pharma
